UEG Week Virtual 2020 - October 11-13, 2020 NEW OUP Gastro Content
As UEGW 2020 will be a virtual congress this year we’d like to draw your attention to some top-quality, peer-reviewed papers. Supplied as Trustrack Links they can be hosted on your website, sent out in mailings embedded in digital ad campaigns or even integrated into Virtual Congress opportunities.
If you are interested in a quote for these or any other papers please CONTACT US.
NEWCONTENT + OUP 10% DISCOUNT on all ePrint Orders confirmed by 31st October
Journal of Crohns & Colitis Author: Martin A et al • Published: January 2020 Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study.
Author: Torres J et al • Published: January 2020 ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
Author: Adamina M et al • Published: November 2019 ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.
Author: Lukas M et al • Published: January 2020 Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: Short-term experience from a single tertiary clinical center.
Author: Siegmund B et al • Published: January 2020 JAKs in the new treatment paradigms of IBD.
Author: Kotwani P et al • Published: February 2020 Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience.
Author: Schreiber S et al • Published: March 2020 Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
Author: Peverelle M et al • Published: March 2020 Ustekinumab is a safe and effective biologic agent for Crohn's disease in a Liver Transplant patient.
Author: Honap S et al • Published: April 2020 Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience.
Author: Phillips F M et al • Published: April 2020 Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series
Author: Fumery M et al • Published: September 2020 Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn’s Disease: A Multicenter Study
Inflamatory Bowel Diseases Author: Dubinsky M C et al • Published: August 2020 Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies
Author: Reinisch W et al • Published: July 2020 Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease
Author: Lichtenstein G R et al • Published: August 2020 Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program
